Measurement of LiSA was performed with Hepatus, a newly developed ultrasound machine, with a 3.5-MHz phased array probe (LFP5-1U, Mindray, Re 6S, China). FibroScan with an M probe (Echosens, FibroScan 502, France) was used to measure CAP. The attenuation of ultrasound propagation in the liver tissue is increased by fat accumulation. Therefore, the detection of ultrasonic attenuation coefficient is a quantitative method for evaluating the degree of liver steatosis (10). Both LiSA and CAP measure the total ultrasonic attenuation (go-and-return path) in the liver at 3.5 MHz, which is expressed in decibels per meter (dB/m). CAP measures the ultrasonic attenuation in the liver tissue along the vertical axis of the probe (one dimension), while LiSA detects the mean ultrasonic attenuations in liver tissue at the region of interest (two dimension) (Figure 1A). The actual visual measurement screen of LiSA is shown in Figure 1B.

Liver steatosis analysis (LiSA). (A) The difference between controlled attenuation parameter (CAP) and LiSA in the detection of ultrasound attenuation in the liver. (B) Actual measurement screen of LiSA.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.